Effect of gliclazide modified release on adiponectin, interleukin‐6, and tumor necrosis factor‐α plasma levels in individuals with type 2 diabetes mellitus

Abstract

Gliclazide MR improves glycemic control and, in addition, has a positive influence on the plasma level of some inflammatory markers and adiponectin. Increased plasma adiponectin and decreased plasma IL-6, and TNF-alpha levels may explain, at least in part, the anti-atherogenic action of this drug reported elsewhere.

AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study

“…Gliclazide had no effect on AMPK activity in 3T3-L1 adipocytes and has been reported to increase plasma adiponectin concentrations in individuals with type 2 diabetes [33], whereas we have shown that metformin is capable of directly stimulating 3T3-L1 adipocyte AMPK activity. This latter observation is in agreement with previous reports in 3T3-L1 adipocytes [34] and isolated human subcutaneous adipocytes stimulated with metformin in vitro [35].…”

Changes in adiponectin level and fat distribution in patients with type 2 diabetes

“…Indeed, a majority of studies have shown a neutral [14,24,[26][27][28] or even negative [29] effect of metformin on adiponectin secretion. On the contrary, some other studies have demonstrated a positive effect of metformin [30] and gliclazide [31] on adiponectin levels, suggesting that agents different than TZDs may increase adiponectin concentrations by mechanisms other than exclusively by the enhancement of PPAR-c activity. Such mechanisms might possibly involve the upregulation of adiponectin gene expression in subcutaneous adipose tissue induced by glucose-lowering drugs [32] or their interaction with AMPactivated protein activity [33].…”

Effects of sulfonylurea treatment on blood plasminogen activator inhibitor-1 levels in patients with type 2 diabetes mellitus: A network meta-analysis

“…These three sulfonylureas may doi: 10.7243/2050-0866-7-1 have different effects on the metabolic system. For example, gliclazide has been demonstrated to directly improve oxidative stress and inflammatory cytokine levels [8,9], whereas glimepiride reportedly promotes glucose uptake at the peripheral tissue level and improves insulin resistance [10]. In other words, presumably sulfonylureas probably lower blood PAI-1 levels by suppressing inflammatory cytokines, oxidative stress, and insulin resistance; however, we hypothesized that the effect of these three sulfonylureas on blood PAI-1 levels could differ depending on the drug (drug-effect).…”

“…Gliclazide exerts an oxidative stress-lowering effect, which is considered to be stronger than that of glibenclamideor glimepiride [33]. Furthermore, gliclazide therapy reportedly lowers TNF-α and increases adiponectin levels [8]. Reduced TNF-α and elevated adiponectin levels correlate with improved insulin resistance, which is thought to be associated with low blood PAI-1 levels [34,35].…”